All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
The 59th Annual Meeting & Exposition of the American Society of Hematology (ASH) took place in Atlanta, GA, on December 9–12, 2017. On Tuesday 12th December, a late-breaking abstract session was held , with abstract #LBA-2 being presented during this session titled “Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study” by John F Seymour Peter MacCallum Centre and Royal Melbourne Hospital, Melbourne, Australia, and colleagues.
In a previous Phase Ib study, the combination of venetoclax and rituximab was found to be effective with acceptable safety results in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This data lead to evaluating this combination in a Phase III (MURANO) study to assess efficacy and safety compared with standard immunochemotherapy.
Dr Seymour concluded that VR was superior to BR in prolonging PFS and also that this trend was consistent across the subgroup analyses. He also noted that “the secondary endpoints were in favor of venetoclax and rituximab in particular the MRD negativity rate that was maintained over time. Thus overall, venetoclax plus rituximab should be considered as a suitable standard of therapy option for patients with relapsed or refractory CLL.”
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox